You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

CHOP+OBIN

Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone

You might also be interested in